Our Panx1 channel blocker platform
Pannex Therapeutics leverages advanced in silico modeling and channel docking studies, utilizing the 3D structure of human Panx1 and insights from nonspecific inhibitors to design a robust platform of small molecule Panx1 blockers.
Our patent-protected platform includes hundreds of rationally designed Panx1 blockers, many validated through rigorous testing. This innovation has led to the advancement of lead candidates in high-value therapeutic areas, positioning us to address critical unmet medical needs.
By capitalizing on the untapped potential of Panx1 blockers, we are positioned to deliver first-in-class treatments that address critical unmet medical needs, driving significant value for patients and stakeholders alike.
Panx1’s pivotal role in multiple disease pathways in oncology and neurology presents the company with significant opportunities to expand its portfolio and enhances its value across a range of indications.
Development pipeline
We are leveraging our Panx1 platform to explore its potential in oncology and neurology. Besides a focus on advancing triple-negative breast cancer (TNBC) into clinical development, we have also achieved key efficacy milestones in neurological diseases. Our approach combines independent development in oncology with partnerships to drive progress in neurology.
